Biolase (BIOLQ) 8-K Regulation FD Disclosure

BIOLASE Technology, Inc.

Federico Pignatelli, Chairman, CEO & President

UBS

13

Annual Global Life Sciences Conference

September 19-21, 2011, New York City

NASDAQ:

BLTI

www.biolase.com

th

Exhibit 99.1

Safe Harbor Statement

PAGE

2

This presentation may contain forward-looking statements that are based on our current expectations, estimates and

projections about our industry as well as management’s beliefs and assumptions. Words such as “anticipates,”

“expects,” “intends,” “plans,”  “believes,”  “seeks,” “estimates,” “may,” “will,” and variations of these words or similar

expressions are intended to identify forward-looking statements. These statements include projections about our future

earnings and margins and speak only as of the date hereof. Such statements are based upon the information available

to us now and are subject to change. We will not necessarily inform you of such changes. These statements are not

guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to

predict. Therefore our actual results could differ materially and adversely from those expressed in any forward-looking

statements as a result of various factors. The important factors which could cause actual results to differ materially

from those in the forward-looking statements include, among others, a downturn or leveling off of demand for our

products due to the availability and pricing of competing products and technologies, adverse international market or

political conditions, a domestic economic recession, the volume and pricing of product sales, our ability to control 

costs, intellectual property disputes, the effects of natural disasters and other events beyond our control and other

factors including those detailed in BIOLASE’s filings with the Securities and Exchange Commission including its prior

filings on Form 10-K and 10-Q.

Market Data

PAGE 3

As of September 15, 2011:

Share price……………….....………………………...…………......................................................................

Shares issued and outstanding……………………………………………..…..….….....….……………

Public float (shares held by others than the CEO and Board).…………………..…......….………..…

Average daily volume (three month average)…………………………………..….……………….……......

Market capitalization……………………………………………………………...........………………..

Percentage of shares held by institutional holders (at June 30, 2011)..……..............………

Short position………………………………………………………………………….……………………….

Dividend yield…………………………………………………………………….…………..…….….

$3.53

30,300,000

29,000,000

590,000

$106,900,000

approximately 57%

6,952,000

4% Annual Stock

BIOLASE is currently covered by analysts from Needham & Company LLC, WJB Capital Group, and Rodman & Renshaw

LLC and is part of both the Russell Global and Russell 2000 Indexes. 

Financial Highlights

PAGE 4

Turnaround:

For

the

nine

month

period

ended

June

30,

2011,

BIOLASE

generated

non-GAAP

net

income

of approximately $885,000, as compared to a non-GAAP net loss of approximately $9.3 million for the nine

month period ended June 30, 2010.

Insider Purchases:

During 2011, officers and directors have purchased approximately 109,700 shares of

stock in the open market for approximately $440,000.  In addition, officers and directors have converted

approximately 523,000 options into shares of common stock.

Employee

Stakeholders:

BIOLASE’s

entire

executive

team

holds

options

to

purchase

common

stock. 

As of June 30, 2011, approximately 82 employees held 3,000,000 options.

CEO

Stakeholder:

BIOLASE’s

Chairman,

President,

and

CEO,

Federico

Pignatelli,

has

an

annual

salary

of one dollar.  Mr. Pignatelli owns approximately 1.7 million shares of stock and 200,000 options to purchase

common stock.  The only way that Mr. Pignatelli will make money in 2011 is as a shareholder.

BIOLASE is About Revolutionizing Surgery in

Dentistry

and

Medicine

PAGE 5

New management is transforming BIOLASE from a one product, one segment company of the past to a

multi-product

and

multi-segment

platform

company

that

will

be

better

diversified

in

2012

and

beyond

and

better

positioned

for

substantial

growth

compared

to

the

“old”

BIOLASE.

In

2011,

BIOLASE

has

better

positioned itself product-wise due to the release of its revolutionary all-tissue WaterLase iPlus, the growing

interest in the iLase, a battery operated handheld diode laser, and the introduction of a full line of digital

imaging

devices.

BIOLASE

is

also

working

diligently

to

leverage

its

revolutionary

IP

in

new

market

segments, including ophthalmology, orthopedics, dermatology, podiatry, and pain management.  We have

a lower cost structure and a growing direct sales force which will allow us to leverage our earnings

compared to BIOLASE of the past.  

BIOLASE

is

NOT

just

another

medical

equipment

company!

How

has

BIOLASE

Revolutionized

Surgery?

Years of engineering and research at BIOLASE led to the discovery that the Er,Cr:YSGG (2796nm) laser

crystal (Erbium, Chromium doped Yttrium-Scandium-Gallium-Garnet) has the highest level of absorption

in

water

molecules

contained

in

human

tissue.

This

absorption

creates

an

expansion

and

vaporization

of the water molecules causing a biological ablation of human tissue including teeth, dentin, bone, gum,

skin and the eye).  For example, tooth enamel contains up to 5% water, dentin and bone contain up to 25% water,

soft tissue (gum tissue and skin) contains up to 80% water, and the eye contains up to 90% water. 

…through

the

science

of

WaterLase!

PAGE 6

Conventional Surgical Devices include the scalpel, high speed drill,

electrosurge, electric bone saws, and heat generating lasers.

Why

BIOLASE

WaterLase

Technology

in

Dentistry?

Traditional

high-speed

drills

work

by

FRICTION

which

creates

HEAT

which

causes

PAIN.

This

PAIN

necessitates injections of ANESTHESIA which results in PAIN and

NUMB LIPS.  In

addition, the lack of feeling from the numbing injections can lead to THERMAL DAMAGE

which can lead to PULPAL DEATH and result in a ROOT CANAL.

The

traditional

high-speed

drill

also

causes

VIBRATION,

which

causes

PAIN

and

leads

to

MICROFRACTURES.  These MICROFRACTURES allow BACTERIA to penetrate the tooth

which causes further DECAY and the FRACTURING of teeth.

High

speed

drills

also

require

the

use

of

BURS

which

even

after

autoclaving

have a 15% chance of carrying pathogenic micro-organisms.  Needles

and files can also carry bacteria.  That means in traditional dentistry the

patient has a 1 in 6 chance of cross contamination.

WaterLase energy

does not create heat or vibration so there is NO PAIN.  Further, the

WaterLase is bactericidal, antiviral and essentially eliminates the risk of cross contamination.

PAGE 7

Traditional Dentistry

The painting Cavadenti, the Tooth Puller, by Caravaggio, circa 1608

PAGE 8

Alternative and Advanced Hi-Tech Dentistry

Atraumatic Pediatric Tooth Extraction

The aiming beam on

the NEW WaterLase 

iPlus is green.  This

red beam featured in

the previous

generation of

WaterLase products

does not cut the

tissue.  Tissue is cut

biologically, with

water at the

molecular level.

Using BIOLASE WaterLase Systems, including our new WaterLase iPlus System:

PAGE 9

The iPlus features an

intuitive, touch-based

computer screen,

similar to a tablet

personal computer. 

It is designed to

allow for remote

servicing and

software upgrades.

Alternative Dentistry is Less Frightening

•

There

are

160,000

dentists

currently

serving

a

population

of

300

million

Americans which means that 75 million Americans are avoiding dental care

because

of

fear.

This

equates

to

an

average

of

470

patients

per

dentist!

•

Patients spend about $1,000 per year on dental care, meaning that U.S.

dentists are missing out on an average of $470,000 of potential revenue,

every year.  If a dentist that adopts painless WaterLase Technology realizes

only half of this potential, they could earn an additional $235,000 in annual

revenue by just

serving fearful patients. 

PAGE 10

Using

the

dental

drill

offers

more

of

the

same

which

is

pain,

local

anesthetic,

swelling,

pain

killers,

micro-

fractures

and

cross

contamination.

WaterLase

technology

offers

a

biological

solution

with

none

of

the

downsides  

of

traditional

dentistry:

NO drill, NO shot, NO pain, and NO cross contamination of bacteria or viruses.

According to the ADA, nearly 25% of all Americans avoid

dentists because they are afraid of dental drills and needles. 

WaterLase’s

Amazing

Return

on

Investment

•

WaterLase technology enables traditional dentists to perform procedures that

they currently refer out to specialists or WaterLase dentists, for example:

•

Gingivectomy = $160

•

Perio Treatment = $375

•

Hard-tissue Crown Lengthening = $520

•

Herpetic or Aphthous Ulcer = $308

•

Frenectomy = $355

•

This equates to $250-$750 per day in additional revenue

•

These procedures are easy to learn and training is included in the cost of the

WaterLase.

Monthly Lease Payment

New Monthly Revenue Generated

Approx. $1,000

$5,000

–

$15,000

PAGE 11

A

dentists’

return on

investment can be

between 500%       

and

1,500%!

Technology Supported by Scientific Data

Substantial Data:

•

The effectiveness of dental   

lasers is proven and well   

researched.

•

Clinical data and peer-

reviewed specialty journals   

substantiate the effectiveness of

laser treatment in a wide variety

of procedures.

PAGE 12

Some of the Dental Schools that are Teaching

WaterLase Technology around the World   

PAGE 13

WaterLase High Speed Cutting

PAGE 14

WaterLase vs. Drill     

PAGE 15

1. Dental Health Magazine 2. Dental Burs and Endodontic Files: Are Routine Sterilization Procedures Effective?: Archie Morrison,

DDS, MS, FRCD(C); Susan Conrod, DDS JCDA •

www.cda-adc.ca/jcda •

February 2009, Vol. 75, No. 1.  3. Contaminated dental

instruments: Smith A, Dickson M, Aitken J, Bagg J.J Hosp Infect.

2002 Jul;51(3):233-5.  4. The antimicrobial efficacy of the erbium, chromium:yttrium-scandium-gallium-garnet laser with radial emitting tips on root canal dentin walls infected with

Enterococcus faecalis: Wanda Gordon, DMD, Vahid A. Atabakhsh, DDS, Fernando Meza, DMD, Aaron Doms, DDS, Roni Nissan, DMD, Ioana Rizoiu, MS and Roy H. Stevens, DDS, MS JADA 2007; 138(7): 992-1002.

Warning:

Patients Urged to Ask their Dentists

About the Risk of Cross Contamination!

Studies indicate that cross contamination is a huge

threat

1,2,3,4

:

•

The CDC defines cross-contamination as the act of spreading

bacteria and viruses from one surface to another. Blood-borne

viruses have the ability to live on objects and surfaces for as long

as a week.

•

Even something as innocuous as the chain and holder that fastens

a patient’s protective bib in place can contain 1,000 times more

bacteria than disposable or sterilized chains.

•

Sterilization techniques used for the dental burs used with the high

speed drill and endodontic files used in root canals are not 100%

effective.  This is a serious health threat for many people.

PAGE 16

Because NO Pain, NO Tissue Damage & NO Risk of Cross-Contamination:

WaterLase MD™

reduced E. faecalis 2.86

times more effectively than NaOCl³

1. Dental Burs and Endodontic Files: Are Routine Sterilization Procedures Effective?: Archie Morrison, DDS, MS, FRCD(C); Susan Conrod, DDS JCDA •

www.cda-adc.ca/jcda •

February 2009, Vol. 75, No. 1.  2. Contaminated dental instruments:

Smith A, Dickson M, Aitken J, Bagg J.J Hosp Infect. 2002 Jul;51(3):233-5.  3. The antimicrobial efficacy of the erbium, chromium:yttrium-scandium-gallium-garnet laser with radial emitting tips on root canal dentin walls infected with

Enterococcus faecalis: Wanda Gordon, DMD, Vahid A. Atabakhsh, DDS, Fernando Meza, DMD, Aaron Doms, DDS, Roni Nissan, DMD, Ioana Rizoiu, MS and Roy H. Stevens, DDS, MS JADA 2007; 138(7): 992-1002

Burs and Endo Files:

•

15%

of

“sterilized”

burs

and

up

to

76%

of

“sterilized”

endodontic

files

carry

pathogenic

micro-organisms.

•

Complex and rugged bur surface difficult to

sterilize.

•

Autoclaving fails 15% of the time to completely

decontaminate burs

WaterLase Tips:

•

Smooth tip surface does not harbor debris or

bacteria like abrasive surface of burs or files.

•

YSGG laser energy is bacteriacidal.

•

Single-use, disposable tips that work without

the need to contact tissue.  Also eliminates

accidental sticks with contaminated burs.

WaterLase Laser Technology Eliminates the Risk

of Cross Contamination and Contagion

PAGE 17

2

1

3

1,

Award winning IP:

Recognized for innovation, leadership, and the development of numerous disruptive technologies, most

notably the development of a new surgical system to cut human tissue in a biological and atraumatic way.

Received Astrum Award at MDB Capital’s 2011 Bright Lights Conference.

Strategy:

Currently working with highly regarded IP consulting company to analyze our patent families and 

determine those with the greatest potential:

–

Dentistry (including new lasers for hard and soft tissue, a laser toothbrush, flavored water)

–

Ophthalmology (including procedures for presbyopia, glaucoma, maxillofacial surgery)

–

Orthopedics and pain management (including use as a general surgical knife)

Internal development, licensing, and legal action against infringers.

Intellectual Property

PAGE 18

•

•

•

•

Current

Status:

BIOLASE

currently

has

279

issued

and

pending

patents,

70%

of

which

are

related

to

our

core Er;Cr:YSGG technology and medical lasers.

Filing

costs

and

maintenance

are

closely

monitored.

Funding

for

redundant

patents

and

patents

with

a

low-

probability for issuance are stopped.

Patent Portfolio

Issued

Pending

Total

U.S.

84

46

130

International

74

75

149

Total

158

122

279

PAGE 19

Current Line of BIOLASE Products

All-tissue

dental

lasers:

Our

all-tissue

lasers

include

our

new

flagship

laser,

the

revolutionary

WaterLase

iPlus,

and

the

WaterLase

MD

Turbo.

Diode

soft-tissue

dental

lasers:

Our

soft

tissue

lasers

include

the

ezLase

total

diode       

solution,

which

offers

power

and

portability,

and

the

revolutionary

iLase,

a

portable

diode

laser

with

no

foot

pedal,

power

cord,

or

external

controls.

Medical:

The

Diolase

10

offers

high

intensity

laser

therapy

in

the

palm

of

your

hand

for

pain

management.

Digital

Imaging:

We

offer

a

full

line

of

digital

imaging

equipment,

including

cone

beam

3-D

dental

imaging

and

CAD/CAM

digital

dental

impressions.

PAGE 20

Patented laser toothbrush for Home Use

•

BIOLASE is currently developing a laser toothbrush for consumer home-use in connection with a license

agreement with The Proctor and Gamble Company (“P&G”).

•

Research indicates that a laser toothbrush for home-use will whiten teeth, disinfect teeth and gums, bio-

stimulate

teeth

and

gums,

relieve

pain,

and

perform

photodynamic

therapy.

•

No other product currently on the market can perform all of these functions.

Patented flavored and sterile water

•

Flavored for patient comfort.

•

Sterile for waterline disinfection of conventional dental chair equipment and lasers.

Soft-tissue lasers

•

BIOLASE is engineering a more powerful diode soft-tissue laser that will offer the user multiple

wavelengths and power up to 40 watts. 

Further Opportunities to Expand in Dentistry

PAGE 21

With

our

patented

WaterLase

and

diode

technologies,

we

have

created

technological

platforms

that

have

the

ability

to

extend

far

outside

of

dentistry.

This

expansion

into

new

markets

is

a

fundamental

effort

within

BIOLASE.

We

expect

to

greatly

expand

our

addressable

markets

in

the

coming

years

which,

we

believe,

has

the

potential

to 

substantially

increase

our

revenues.

Each

of

these

potential

markets

represents

a

multi-

billion

dollar

opportunity.

Ophthalmology:

We

currently

hold

13

issued

and

20

pending

U.S.

and

International

patents

in

four

patent

families

in

the

field

of

ophthalmology,

giving

us

a

wide

range

of

applications

and

coverage.

Our

patented

technology

has

the

capability

to

restore

the

elasticity

of

the

eye

and

allow

it

to

return

to

normal

function,

eliminating

presbyopia.

Management

has

established

a

new

subsidiary,

OCULASE,

which

will

own

and

develop

BIOLASE’s

ophthalmic

assets

and

technologies.  

Further Opportunities to Expand in Medicine

PAGE 22

Podiatry:

We

have

found

that

our

Diolase

10

technology

is

very

effective

in

the

treatment

of

nail

fungus

and

we

are

completing

the

clinical

and

regulatory

requirements

necessary

to

enter

the

market.

Orthopedics:

We

are

working

with

several

key

manufacturers

and

universities

to

provide

solutions

that

are

not

currently

available.

We

are

investigating

opportunities

for

several

orthopedic

applications

and

anticipate

filing

several

510(k)

applications

over

the

next

12

months.

Aesthetics:

We

have

various

FDA

approvals

for

applications

in

dermatology,

plastic

surgery,

and

oculoplastics

and

are

currently

investigating

options

for

entering

these

markets.

Pain

Management:

We

anticipate

launching

a

new

deep-tissue

hand

piece

and

upgraded

laser

for

pain

therapy

in

the

near

term

which

will

coincide

with

a

new

marketing

campaign.

PAGE 23

Further Opportunities to Expand in Medicine (Continued)

How BIOLASE is positioned for a successful turnaround:

BIOLASE has a better organizational structure, better cost control, and more efficient & effective management

than ever before.

The BIOLASE brand is currently known by over 80% of North American dentists and is growing internationally.

BIOLASE has the largest installed base of dental lasers which equates to recurring revenues from consumables,

warranties, and service contracts.

BIOLASE has more products available than ever before.

BIOLASE has more clinical trials, more FDA approvals, and more patents and pending patents than ever before.

Foundation for a Successful Recovery

PAGE 24

•

•

•

•

•

How BIOLASE is Positioned in the Dental Market   

BIOLASE United States

BIOLASE International

Total: 12,500

Total: 5,500

Grand Total: 18,000

2,800

2,700

5,700

6,800

PAGE 25

Owning BIOLASE Means Owning the Hard

Tissue Dental Laser Market…

Source: Biolase Technology Licensing Reports

PAGE 26

Biolase

80%

…and the Overall Dental Laser Market.

Biolase

45%

Source: iData Research Inc.

2009 US Dental Laser Market: Hard & Soft Tissue

PAGE 27

Our Market Opportunity in Dentistry

BIOLASE’s global market opportunity is tremendous! 

•

176,000

dentists

in

the

US

and

Canada.

1

•

Over

1.2

million

dentists

in

134

countries.

2

•

18,000 systems in over 11,000 practices.

•

Every 1% of further market penetration is equal to an

opportunity of well over $600 million, including

consumables.

Estimated total global market of 1,200,000,

which is growing rapidly due to new markets

such as China, India, and Indonesia.

18,000

3

systems sold worldwide.

1. American Dental Association.  2. World Federation of Dentistry.  3. 1998-present over 17,300 BIOLASE systems sold.

PAGE 28

Our current market penetration is approximately

3% in the United States and slightly less than 1%

internationally! 

Incredible Opportunity in Emerging Markets

North America

176,000 dentists

1 dentist / 1,900 population

Western Europe

240,000

dentists

1 dentist / 1,800

population

Latin America

298,000

dentists

1 dentist / 5,600 population

Eastern Europe

120,000

dentists

1 dentist / 4,000 population

Middle East

19,000

dentists

1 dentist / 3,100 population

India

35,000

dentists

1 dentist / 33,900 population

China

16,000 dentists

1 dentist / 82,300 population

Rest of Asia

43,000 dentists

1 dentist / 14,000

population

Worldwide Total

1,200,000 dentists

1. World Federation of Dentistry

Practicing Dentists

1

Japan

63,000 dentists

1 dentist / 2,000

population

PAGE 29

BIOLASE is the Global Leader in Dental Lasers:

•

Over 18,000 laser systems sold to over 11,000 dental

practices in over 50  countries worldwide.

•

We have over 170 employees worldwide

•

We also have training facilities in Charlotte, NC, St.

Louis, MO, and Irvine, CA.

BIOLASE Technology, Inc. Today

Company Headquarters in Irvine, California

PAGE 30

•

We have sales offices in the U.S., Floss

(Germany), Madrid (Spain), Shanghai (China),

and Mumbai (India), with expansion planned

in Dubai (UAE), and Rio de Janero (Brazil).

BIOLASE Europe in Floss, Germany

Operations

•

Our 57,000 sq. ft. facility houses administrative, sales, 

marketing, customer care, training, R&D and manufacturing.  

Our Irvine facility can accommodate growth to $250 million.

•

We are ISO 9001 certified and FDA GMP with clean room

operations.  We also have manufacturing capabilities in

Floss, Germany.

PAGE 31

•

Nearly 100% of our components and subassemblies

are manufactured in our facility and/or the U.S.

•

We have a highly skilled R&D team with extensive

medical device and laser development expertise.  

We are highly focused in improving and extending 

our dental and medical product portfolio.

Manufacturing and Research & Development

Recent Developments

Ophthalmology:

In June 2011, BIOLASE entered into an agreement with Daniel S. Durrie, M.D., an

internationally recognized refractive surgeon, to serve as BIOLASE’s primary ophthalmic expert resource and

partner

with

management

to

oversee

the

development

and

execution

of

our

clinical

studies

and

consult

on

ophthalmic

applications

for

our

intellectual

property

portfolio.

Dr.

Durrie

has

been

recognized

as

one

of

the

Top

Ten

Refractive

Surgeons

in

America

and

one

of

the

Fifty

Most

Influential

Ophthalmologists

in

the

World.

He

will

also assist with the formation of a new Advisory board for OCULASE, BIOLASE’s new ophthalmology company,

asssist in recruiting members and serve as the inaugural chairman.  Dr. Durrie agreed to options to acquire

75,000 shares of BIOLASE’s common stock in lieu of cash compensation.

Asian

Offices:

In

June

2011,

BIOLASE

officially

opened

BIOLASE

Technology

Asia

Pacific,

its

Asian

headquarters,

in

Shanghai,

China,

and

a

direct

sales

and

service

office,

BIOLASE

India

Private

Limited,

in

Mumbai, India.

Digital

Imaging

Sales:

At

the

end

of

the

second

quarter,

BIOLASE

received

its

first

orders

for

its

state

of

the

art

dental imaging devices for delivery in the third quarter.

PAGE 32

Recent Developments (continued)

Legal

Settlement:

In

June

2011,

BIOLASE

reached

a

final

settlement

with

Philips

Electronics

(NYSE:PHG)

and Discus Dental LLC, regarding the litigation that Discus brought against BIOLASE in 2010 (Discus was

subsequently acquired by Philips). In the litigation, Discus asserted various claims that BIOLASE's iLase™

personal laser infringed Discus' design patent.  All of Discus' and Philips' claims against BIOLASE were

completely dropped and dismissed in their entirety with prejudice.

Direct

Sales

in

Germany:

BIOLASE

has

regained

the

ability

to

sell

direct

or

through

other

distributors

from Henry Schein Inc. (NASDAQ: HSIC) for all of its international territories and has announced plans to

expand BIOLASE Europe, GMBH, to now include a direct sales force, along with service and support

operations, for the German market.

Additions

to

the

Management

Team:

BIOLASE

has

recently

hired

Richard

Whipp

as

Director

of

Operations

and Ehab Esmail as Vice President of Global Regulatory, Quality and Clinical Affairs.

Private

Placement:

In

June

2011,

BIOLASE

raised

$9

million

from

institutional

investors

in

a

private

placement

through

the

sale

of

1.6

million

shares

of

common

stock

and

812,000

warrants.

PAGE 33

0.5

1.0

Chart & Financial History

20

15

10

5

BLTI

SHARE

PRICE

1994-2006 Pignatelli

Chairman of the Board

Exclusive distribution partnership with

Henry Schein Aug 2006–Aug 2010

Aug 2010-Present

Pignatelli CEO &

Board Chairman

1998  FDA

Clearance

WaterLase

PAGE 34

BIOLASE Technology, Inc.

Federico

Pignatelli,

Chairman,

CEO

&

President

UBS

13

th

Annual Global Life Sciences Conference

September 19-21, 2011, New York City

NASDAQ:

BLTI

www.biolase.com